| Literature DB >> 30860811 |
Junxia Zhang1,2,3, Jichun Zhou1, Tingting Zhang1, Zhenxi Niu2,4, Juan Wang1, Jiaomei Guo1, Zhenguo Li1, Zhenzhong Zhang2,3.
Abstract
In order to increase the oral bioavailability and antidiabetic effect of amentoflavone with multimechanisms, an oral micelle system was developed by using a N-vinyl pyrrolidone-maleate-guerbet alcohol monoester polymer for the first time, which was designated as P(NVP-MGAM)/AF. After oral administration, P(NVP-MGAM)/AF enhanced the oral bioavailability of amentoflavone, which was approximately 3.2 times that of amentoflavone solution. The animal study using the KKAy insulin-resistant diabetes mouse model indicated that it regulates the expression and activity of downstream signaling factors and proteins by lowering blood lipids, reducing inflammatory responses and activating the peroxisome proliferator-activated receptor (PPAR) γ signaling pathway and PI3K/Akt signaling pathway. After being made into micelles, it is more effective because of its better absorbability and bioavailability. The results from this study provide a theoretical basis for the clinical application of amentoflavone for diabetes treatment. The oral micelles of P(NVP-MGAM)/AF may become one of the most potent drugs in the treatment of diabetes mellitus, which opens up a new way for the prevention and treatment of diabetes.Entities:
Keywords: N-vinyl pyrrolidone-maleate-guerbet alcohol monoester polymer; amentoflavone; bioavailability; oral micelle; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2019 PMID: 30860811 DOI: 10.1021/acsami.9b03275
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN: 1944-8244 Impact factor: 9.229